-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
![epigenomics 2022 featured](https://volition.com/wp-content/uploads/2024/02/epigenomics-2022-featured-.jpg)
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib
- Share
- Tweet
- Share on Facebook
- Share
![Epigenomics 2022 thumbnail](https://volition.com/wp-content/uploads/2024/02/Epigenomics-2022-thumbnail.jpg)
![Epigenomics 2022 thumbnail](https://volition.com/wp-content/uploads/2024/02/Epigenomics-2022-thumbnail.jpg)
Paper titled: Predictive significance of circulating histonesin hepatocellular carcinoma patients treated with sorafenib.
Salani, Latarani, Casadei-Gardini et al.
Published in Epigenomics 2022
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields